Abstract
Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering on the development of atherosclerosis. In contrast, the recently developed glucagon like peptide-1-based therapy using glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors has numerous beneficial effects in the management of hyperglycemia with less risk of hypoglycemia and weight gain. Glucagon-like peptide-1-based therapy also lowers blood pressure and blood lipids and thus may prevent progression of atherosclerosis. Furthermore, glucagonlike peptide-1 receptors are abundantly expressed in vascular cells such as endothelial cells, monocyte/macrophages and smooth muscle cells. Recent studies suggest that the anti-inflammatory and vasodilatory properties of glucagon-like peptide-1 signaling on endothelial cells, its anti-inflammatory effect on macrophages and anti-proliferative effects on smooth muscle cells may halt atherosclerosis. Although large clinical trials are required to confirm these beneficial effects, glucagon-like peptide-1-based therapy could provide both glucose lowering and protection against cardiovascular diseases in patients with type 2 diabetes.
Keywords: Atherosclerosis, diabetes, endothelial cells, glucagon-like peptide-1, macrophage/monocyte, smooth muscle cells
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Glucagon Like Peptide-1 and Atherosclerosis
Volume: 10 Issue: 4
Author(s): Tomoya Mita and Hirotaka Watada
Affiliation:
Keywords: Atherosclerosis, diabetes, endothelial cells, glucagon-like peptide-1, macrophage/monocyte, smooth muscle cells
Abstract: Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering on the development of atherosclerosis. In contrast, the recently developed glucagon like peptide-1-based therapy using glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors has numerous beneficial effects in the management of hyperglycemia with less risk of hypoglycemia and weight gain. Glucagon-like peptide-1-based therapy also lowers blood pressure and blood lipids and thus may prevent progression of atherosclerosis. Furthermore, glucagonlike peptide-1 receptors are abundantly expressed in vascular cells such as endothelial cells, monocyte/macrophages and smooth muscle cells. Recent studies suggest that the anti-inflammatory and vasodilatory properties of glucagon-like peptide-1 signaling on endothelial cells, its anti-inflammatory effect on macrophages and anti-proliferative effects on smooth muscle cells may halt atherosclerosis. Although large clinical trials are required to confirm these beneficial effects, glucagon-like peptide-1-based therapy could provide both glucose lowering and protection against cardiovascular diseases in patients with type 2 diabetes.
Export Options
About this article
Cite this article as:
Mita Tomoya and Watada Hirotaka, Glucagon Like Peptide-1 and Atherosclerosis, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (4) . https://dx.doi.org/10.2174/187152512803530388
DOI https://dx.doi.org/10.2174/187152512803530388 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Soybean and Processed Soy Foods Ingredients, and Their Role in Cardiometabolic Risk Prevention
Recent Patents on Food, Nutrition & Agriculture WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Beta Cell Regeneration in Adult Mice: Controversy Over the Involvement of Stem Cells
Current Stem Cell Research & Therapy Epigenetic Basis of Individual Variability to Major Psychosis
Current Pharmacogenomics and Personalized Medicine Walking the Oxidative Stress Tightrope: A Perspective from the Naked Mole-Rat, the Longest-Living Rodent
Current Pharmaceutical Design Antiplatelet for Coronary Artery Disease in Specific Condition “No Size Fits All”
Current Pharmaceutical Design Inflammation Markers in Essential Hypertension
Medicinal Chemistry SGLT2 Inhibitors in Diabetes Mellitus Treatment
Reviews on Recent Clinical Trials Regulatory Role of Heat Shock Proteins in the Pathogenesis of Type 1 and Type 2 Diabetes
Current Immunology Reviews (Discontinued) Current HIV Treatment Guidelines - An Overview
Current Pharmaceutical Design Epicardial and Intramyocardial Adipose Tissue: The Enemy within
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Current Vascular Pharmacology Diagnosis and New Approaches in the Therapy of Gestational Diabetes Mellitus
Current Diabetes Reviews Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design Pre-clinical Validation of Mito-targeted Nano-engineered Flavonoids Isolated From Selaginella bryopteris (Sanjeevani) As A Novel Cancer Prevention Strategy
Anti-Cancer Agents in Medicinal Chemistry Young Stroke Patients Treated with Intravenous Thrombolysis have a More Favorable Outcome and Mortality Compared with Older Patients
Current Neurovascular Research